Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis

CLIN GASTROENTEROL H. 2024 [Epub ahead of print].

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal ALP level associated with complication-free survival gain?
Corpechot C, Lemoinne S, Soret P, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza A, Lytvyak E, Pares A, Olivas I, Eaton J, Osman K, Schramm C, Sebode M, Lohse A, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo F, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil A, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer A, Deibel A, Bruns T, Große K, Wetten A, Dyson J, Jones D, Dumortier J, Pageaux G, de Lédinghen V, Chazouillères O, Carrat F
HEPATOLOGY. 2024;79(1):39-48.

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Kocheise L, Piseddu I, Vonderlin J, Tjwa E, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Barciela M, Gevers T, Beretta-Piccoli B, Londoño M, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter J, Fründt T, Lohse A, Huber S, von Felden J, Sebode M, Schulze K
FRONT IMMUNOL. 2024;15:1369747.

Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis
Poch T, Bahn J, Casar C, Krause J, Evangelakos I, Gilladi H, Kunzmann L, Laschtowitz A, Iuso N, Schäfer A, Liebig L, Steinmann S, Sebode M, Folseraas T, Engesæter L, Karlsen T, Franke A, Metabolic Sciences, Max Delbrück Centre for Molecular Medicine in the Helmholtz Association C, Schlein C, Galun E, Huber S, Lohse A, Gagliani N, Schwinge D, Schramm C
CELL REP MED. 2024;5(7):101620.

Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R-LIVER)
Schregel I, Papp M, Sipeki N, Kovats P, Taubert R, Engel B, Campos-Murguia A, Dalekos G, Gatselis N, Zachou K, Milkiewicz P, Janik M, Raszeja-Wyszomirska J, Ytting H, Braun F, Casar C, Sebode M, Lohse A, Schramm C
LIVER INT. 2024;44(10):2687-2699.

Optimizing thiopurine therapy in autoimmune hepatitis: A multi-center study on monitoring metabolite profiles and co-therapy with allopurinol
Weltzsch J, Bartel C, Waldmann M, Renné T, Schulze S, Terziroli Beretta-Piccoli B, Papp M, Ye O, Ronca V, Sebode M, Lohse A, Schramm C, Hartl J
HEPATOLOGY. 2024;80(5):1026-1040.

HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells
Zecher B, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick M, Yuki Y, Martin M, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller L, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer M, Poch T, Sebode M, , Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer K, Schumacher U, Sauter G, Carrington M, Franke A, Bunders M, Schramm C, Altfeld M
GUT. 2024;73(2):325-337.

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
Andrade R, Aithal G, de Boer Y, Liberal R, Gerbes A, Regev A, Terziroli Beretta-Piccoli B, Schramm C, Kleiner D, De Martin E, Kullak-Ublick G, Stirnimann G, Devarbhavi H, Vierling J, Manns M, Sebode M, Londoño M, Avigan M, Robles-Diaz M, García-Cortes M, Atallah E, Heneghan M, Chalasani N, Trivedi P, Hayashi P, Taubert R, Fontana R, Weber S, Oo Y, Zen Y, Licata A, Lucena M, Mieli-Vergani G, Vergani D, Björnsson E
J HEPATOL. 2023;79(3):853-866.

Histological and serological features of acute liver injury after SARS-CoV-2 vaccination
Codoni G, Kirchner T, Engel B, Villamil A, Efe C, Stättermayer A, Weltzsch J, Sebode M, Bernsmeier C, Lleo A, Gevers T, Kupčinskas L, Castiella A, Pinazo J, De Martin E, Bobis I, Sandahl T, Pedica F, Invernizzi F, Del Poggio P, Bruns T, Kolev M, Semmo N, Bessone F, Giguet B, Poggi G, Ueno M, Jang H, Elpek G, Soylu N, Cerny A, Wedemeyer H, Vergani D, Mieli-Vergani G, Lucena M, Andrade R, Zen Y, Taubert R, Terziroli Beretta-Piccoli B
JHEP REP. 2023;5(1):100605.

Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis
Hartl J, Rüther D, Duengelhoef P, Brehm T, Steinmann S, Weltzsch J, Glaser F, Sterneck M, Sebode M, Weiler-Normann C, Lütgehetmann M, Schaub G, Haag F, Schramm C, Schulze Zur Wiesch J, Lohse A
LIVER INT. 2023;43(2):393-400.

Right and left liver lobe biopsies by minilaparoscopy reveal clinically significant sampling error in staging and grading of autoimmune hepatitis
Johannes H, Malte W, Alali S, Marcial S, Sören W, Ptashynska A, Christina W, Christoph S, Willhelm L, Till K, Jörg S
LIVER INT. 2023;43(6):1269-1276.

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Kocheise L, Piseddu I, Vonderlin J, Tjwa E, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers T, Terziroli Beretta-Piccoli B, Londoño M, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter J, Fründt T, Lohse A, Huber S, von Felden J, Sebode M, Schulze K
FRONT IMMUNOL. 2023;14:1326078.

Etiology and Outcome of Adult and Pediatric Acute Liver Failure in Europe
Lenz D, Jørgensen M, Kelly D, Cardinale V, Geerts A, Gonçalves Costa I, Fichtner A, Garbade S, Hegen B, Hilberath J, de Kleine R, Kupčinskas L, McLin V, Niesert M, Prado Gonzalez V, Sturm E, Staufner C, Tjwa E, Willemse J, Zecher B, Larsen F, Sebode M, Ytting H
J PEDIATR GASTR NUTR. 2023;77(1):115-120.

Research gaps and opportunities in autoimmune hepatitis-Results of the international autoimmune hepatitis group research workshop 2022
Snijders R, Assis D, Oo Y, Sebode M, Taubert R, Willemse J, Tomsin B, Lohse A, Drenth J, Gevers T
LIVER INT. 2023;43(7):1375-1384.

Accuracy of controlled attenuation parameter measurement for the detection of steatosis in autoimmune liver diseases
Steinmann S, Hartl J, Weidemann S, Füssel K, Kroll C, Sebode M, Lohse A, Schramm C
JHEP REP. 2023;5(12):100898.

Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis
Terziroli Beretta-Piccoli B, Buescher G, Dalekos G, Zachou K, Geerts A, Semmo N, Kolev M, De Martin E, Janik M, Madaleno J, Lalosevic Stojkovic M, Dumortier J, Vanwolleghem T, Schregel I, Steinmann S, Lacaille F, Sebode M
J AUTOIMMUN. 2023;140:103113.

Update: primär biliäre Cholangitis, primär sklerosierende Cholangitis und IgG4-assoziierte Cholangitis
Weltzsch J, Sebode M, Hartl J
GASTROENTEROLOGE. 2023;18:349-359.

SARS-CoV-2 in Pediatric Liver Transplant Recipients: The European Experience
Buescher G, Sebode M, Marjot T, Webb G, Moon A, Barnes E, Barritt A, Cananzi M, Lohse A, Jørgensen M, McLin V
J PEDIATR GASTR NUTR. 2022;74(2):e41-e42.

SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
Duengelhoef P, Hartl J, Rüther D, Steinmann S, Brehm T, Weltzsch J, Glaser F, Schaub G, Sterneck M, Sebode M, Weiler-Normann C, Addo M, Lütgehetmann M, Haag F, Schramm C, Schulze Zur Wiesch J, Lohse A
UNITED EUR GASTROENT. 2022;10(3):319-329.

Hepatische Granulome – eine diagnostische Herausforderung
Horst L, Weidemann S, Lohse A, Sebode M
Z RHEUMATOL. 2022;81(7):567-576.

Microplastics detected in cirrhotic liver tissue
Horvatits T, Tamminga M, Liu B, Sebode M, Carambia A, Fischer L, Püschel K, Huber S, Fischer E
EBIOMEDICINE. 2022;82:.

Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology
Lohse A, Sebode M, Bhathal P, Clouston A, Dienes H, Jain D, Gouw A, Guindi M, Kakar S, Kleiner D, Krech T, Lackner C, Longerich T, Saxena R, Terracciano L, Washington K, Weidemann S, Hübscher S, Tiniakos D
LIVER INT. 2022;42(5):1058-1069.

Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis
Müller A, Casar C, Preti M, Krzikalla D, Gottwick C, Averhoff P, Rosenstiel P, Gelderblom M, Altfeld M, Lohse A, Steinmann S, Sebode M, Krause J, Schwinge D, Schramm C, Carambia A, Herkel J
J HEPATOL. 2022;77(6):1532-1544.

Sarkoidose als Paradebeispiel einer granulomatösen Erkrankung
Oqueka T, Galow S, Simon M, Weidmann A, Stübiger N, Zengin-Sahm E, Sinning C, Krusche M, Ruffer N, Steurer S, Schick-Bengardt X, Sebode M, Horst L, Steinmetz O, Melderis S, Rosenkranz S, Möller K, Jantke H, Klose H
Z RHEUMATOL. 2022;81(7):535-548.

Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care
Rüther D, Weltzsch J, Schramm C, Sebode M, Lohse A
J HEPATOL. 2022;77(1):250-251.

Histological spectrum of autoimmune hepatitis-reply to Fujiwara K. et al
Sebode M, Lohse A, Hübscher S, Tiniakos D
LIVER INT. 2022;42(7):1704-1705.

Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis
Taubert R, Engel B, Diestelhorst J, Hupa-Breier K, Behrendt P, Baerlecken N, Sühs K, Janik M, Zachou K, Sebode M, Schramm C, Londoño M, Habes S, Oo Y, Lalanne C, Pape S, Schubert M, Hust M, Dübel S, Thevis M, Jonigk D, Beimdiek J, Buettner F, Drenth J, Muratori L, Adams D, Dyson J, Renand A, Graupera I, Lohse A, Dalekos G, Milkiewicz P, Stangel M, Maasoumy B, Witte T, Wedemeyer H, Manns M, Jaeckel E
HEPATOLOGY. 2022;75(1):13-27.

One liver, two samples and two diagnoses-An example of how multiple samples by laparoscopically guided liver biopsy can be decisive
Beisel C, Weidemann S, Sebode M
LIVER INT. 2021;41(11):2786-2787.

Author Correction: Auto-aggressive CXCR6+CD8 T cells cause liver immune pathology in NASH
Dudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, Hartmann D, Hüser N, Meiser P, Bayerl F, Inverso D, Wigger J, Sebode M, Öllinger R, Rad R, Hegenbarth S, Anton M, Guillot A, Bowman A, Heide D, Müller F, Ramadori P, Leone V, Garcia-Caceres C, Gruber T, Seifert G, Kabat A, Mallm J, Reider S, Effenberger M, Roth S, Billeter A, Müller-Stich B, Pearce E, Koch-Nolte F, Käser R, Tilg H, Thimme R, Boettler T, Tacke F, Dufour J, Haller D, Murray P, Heeren R, Zehn D, Böttcher J, Heikenwälder M, Knolle P
NATURE. 2021;593(7860):E14.

Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Dudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, Hartmann D, Meiser P, Bayerl F, Inverso D, Wigger J, Sebode M, Öllinger R, Rad R, Hegenbarth S, Anton M, Guillot A, Bowman A, Heide D, Müller F, Ramadori P, Leone V, Garcia-Caceres C, Gruber T, Seifert G, Kabat A, Malm J, Reider S, Effenberger M, Roth S, Billeter A, Müller-Stich B, Pearce E, Koch-Nolte F, Käser R, Tilg H, Thimme R, Böttler T, Tacke F, Dufour J, Haller D, Murray P, Heeren R, Zehn D, Böttcher J, Heikenwälder M, Knolle P
NATURE. 2021;592(7854):444-449.

Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review
Engel B, Laschtowitz A, Janik M, Junge N, Baumann U, Milkiewicz P, Taubert R, Sebode M
EUR J MED GENET. 2021;64(6):104214.

Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"
Lohse A, Sebode M, Vesterhus M
J HEPATOL. 2021;74(3):755-756.

SARS-CoV-2 infection in patients with autoimmune hepatitis
Marjot T, Buescher G, Sebode M, Barnes E, Barritt A, Armstrong M, Baldelli L, Kennedy J, Mercer C, Ozga A, Casar C, Schramm C, Moon A, Webb G, Lohse A
J HEPATOL. 2021;74(6):1335-1343.

Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis
Poch T, Krause J, Casar C, Liwinski T, Glau L, Kaufmann M, Ahrenstorf A, Hess L, Ziegler A, Martrus G, Lunemann S, Sebode M, Li J, Schwinge D, Krebs C, Franke A, Friese M, Oldhafer K, Fischer L, Altfeld M, Lohse A, Huber S, Tolosa E, Gagliani N, Schramm C
J HEPATOL. 2021;75(2):414-423.

Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver
Preti M, Schlott L, Lübbering D, Krzikalla D, Müller A, Schuran F, Poch T, Schakat M, Weidemann S, Lohse A, Weiler-Normann C, Sebode M, Schwinge D, Schramm C, Carambia A, Herkel J
JCI INSIGHT. 2021;6(6):141462.

Drug-induced liver injury at a tertiary care centre in Germany: Model for End-stage Liver Disease is the best predictor of outcome
Reike-Kunze M, Zenouzi R, Hartl J, Krech T, Weidemann S, Sterneck M, Weiler-Normann C, Lohse A, Schramm C, Sebode M
LIVER INT. 2021;41(10):2383-2395.

Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER‬‬‬
Rüther D, Sebode M, Lohse A, Wernicke S, Böttinger E, Casar C, Braun F, Schramm C
CLIN RES HEPATOL GAS. 2021;45(6):.

Bone microarchitecture in patients with autoimmune hepatitis
Schmidt C, Stürznickel J, Strahl A, Oheim R, Weiler-Normann C, Sebode M, Barvencik F, Lohse A, Schinke T, Amling M, Schramm C, Rolvien T
J BONE MINER RES. 2021;36(7):1316-1325.

Europäisches Referenznetzwerk für seltene Lebererkrankungen (ERN RARE-LIVER)
Schulz L, Sebode M, Schramm C, Lohse A
INTERNIST. 2021;62(4):441-448.

Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey
Zecher B, Buescher G, Willemse J, Walmsley M, Taylor A, Leburgue A, Schramm C, Lohse A, Sebode M
UNITED EUR GASTROENT. 2021;9(7):797-808.

Schwere sekundär sklerosierende Cholangitis als Manifestation einer sehr seltenen Grunderkrankung
Zecher B, Zenouzi R, Lang M, Karagiannis P, Clauditz T, Fischer L, Sterneck M, Schramm C, Lohse A, Sebode M
INTERNIST. 2021;62(12):1349-1353.

Features and outcome of AIH patients without elevation of IgG
Hartl J, Miquel R, Zachou K, Wong G, Asghar A, Pape S, Sebode M, Peiseler M, Zenouzi R, Ehlken H, Krech T, Weiler-Normann C, Drenth J, Oo Y, Dalekos G, Heneghan M, Schramm C, Lohse A
JHEP REP. 2020;2(3):100094.

Monocytes as potential mediators of pathogen-induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC)
Kunzmann L, Schoknecht T, Poch T, Henze L, Stein S, Kriz M, Grewe I, Preti M, Hartl J, Pannicke N, Peiseler M, Sebode M, Zenouzi R, Horvatits T, Böttcher M, Petersen B, Weiler-Normann C, Hess L, Ahrenstorf A, Lunemann S, Martrus G, Fischer L, Li J, Carambia A, Kluwe J, Huber S, Lohse A, Franke A, Herkel J, Schramm C, Schwinge D
HEPATOLOGY. 2020;72(4):1310-1326.

A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis
Liwinski T, Casar C, Ruehlemann M, Bang C, Sebode M, Hohenester S, Denk G, Lieb W, Lohse A, Franke A, Schramm C
ALIMENT PHARM THER. 2020;51(12):1417-1428.

Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group
Lohse A, Sebode M, Jørgensen M, Ytting H, Karlsen T, Kelly D, Manns M, Vesterhus M
J HEPATOL. 2020;73(6):1496-1506.

Perforation of the ascending colon during implantation of an indwelling peritoneal catheter: a case report
Paparoupa M, Wege H, Creutzfeldt A, Sebode M, Uzunoglu F, Boenisch O, Nierhaus A, Izbicki J, Kluge S
BMC GASTROENTEROL. 2020;20(1):345.

Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment
Sebode M, Kloppenburg A, Aigner A, Lohse A, Schramm C, Linder R
Z GASTROENTEROL. 2020;58(5):431-438.

Metamizole Has Been Overlooked as a Trigger for Acute Liver Injury and Acute Liver Failure
Sebode M, Lohse A, Schramm C
DTSCH ARZTEBL INT. 2020;117(37):610.

Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury
Sebode M, Reike-Kunze M, Weidemann S, Zenouzi R, Hartl J, Peiseler M, Liwinski T, Schulz L, Weiler-Normann C, Sterneck M, Lohse A, Schramm C
BRIT J CLIN PHARMACO. 2020;86(7):1406-1415.

Das Europäische Referenznetzwerk für seltene Lebererkrankungen (ERN RARE-LIVER): Betroffene Patienten besser versorgen, Konsilangebot für ärztliche Kollegen
Zecher B, Sebode M, Lohse A
Z GASTROENTEROL. 2020;58(10):1006.

Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis
Abdulkarim M, Zenouzi R, Sebode M, Schulz L, Quaas A, Lohse A, Schramm C, Weiler-Normann C
SCAND J GASTROENTERO. 2019;54(11):1391-1396.

TNF-Producing Th1 Cells Are Selectively Expanded in Liver Infiltrates of Patients with Autoimmune Hepatitis
Bovensiepen C, Schakat M, Sebode M, Zenouzi R, Hartl J, Peiseler M, Li J, Henze L, Woestemeier A, Schramm C, Lohse A, Herkel J, Weiler-Normann C
J IMMUNOL. 2019;203(12):3148-3156.

Editorial: post-operative elevation of liver enzymes and modern volatile anaesthetics-guilty as charged?
Laschtowitz A, Sebode M
ALIMENT PHARM THER. 2019;49(9):1245-1246.

Autoimmune hepatitis: Is the autoimmunity in the family?
Sebode M, Lohse A
LIVER INT. 2019;39(1):42-44.

Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis
Sebode M, Wigger J, Filpe P, Fischer L, Weidemann S, Krech T, Weiler-Normann C, Peiseler M, Hartl J, Tolosa E, Herkel J, Schramm C, Lohse A, Arrenberg P
FRONT IMMUNOL. 2019;10:1065.

The Translational Landscape of the Human Heart
van Heesch S, Witte F, Schneider-Lunitz V, Schulz J, Adami E, Faber A, Kirchner M, Maatz H, Blachut S, Sandmann C, Kanda M, Worth C, Schafer S, Calviello L, Merriott R, Patone G, Hummel O, Wyler E, Obermayer B, Mücke M, Lindberg E, Trnka F, Memczak S, Schilling M, Felkin L, Barton P, Quaife N, Vanezis K, Diecke S, Mukai M, Mah N, Oh S, Kurtz A, Schramm C, Schwinge D, Sebode M, Harakalova M, Asselbergs F, Vink A, de Weger R, Viswanathan S, Widjaja A, Gärtner-Rommel A, Milting H, Dos Remedios C, Knosalla C, Mertins P, Landthaler M, Vingron M, Linke W, Seidman J, Seidman C, Rajewsky N, Ohler U, Cook S, Hubner N
CELL. 2019;178(1):242-260.e29.

Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis
Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, von Felden J, Weiler-Normann C, Schramm C, Lohse A
J HEPATOL. 2018;68(4):754-763.

Efficacy and Limitations of Budesonide as a Second-line Treatment for Patients With Autoimmune Hepatitis
Peiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, Pannicke N, Weiler-Normann C, Lohse A, Schramm C
CLIN GASTROENTEROL H. 2018;16(2):260-267.e1.

Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis
Peiseler M, Reiners D, Pinnschmidt H, Sebode M, Jung F, Hartl J, Zenouzi R, Ehlken H, Groth S, Schachschal G, Rösch T, Weiler-Normann C, Lohse A, Schramm C
PLOS ONE. 2018;13(8):.

Variant syndromes of primary biliary cholangitis
Schulz L, Sebode M, Weidemann S, Lohse A
BEST PRACT RES CL GA. 2018;34-35:55-61.

Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda
Sebode M, Hartl J, Vergani D, Lohse A
LIVER INT. 2018;38(1):15-22.

Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance
Sebode M, Weiler-Normann C, Liwinski T, Schramm C
FRONT IMMUNOL. 2018;9:609.

Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret
Zenouzi R, Liwinski T, Yamamura J, Weiler-Normann C, Sebode M, Keller S, Lohse A, Schramm C
ALIMENT PHARM THER. 2018;48(2):169-178.

Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure
Zenouzi R, von der Gablentz J, Heldmann M, Göttlich M, Weiler-Normann C, Sebode M, Ehlken H, Hartl J, Fellbrich A, Siemonsen S, Schramm C, Münte T, Lohse A
PLOS ONE. 2018;13(1):e0190005.

CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood
Schoknecht T, Schwinge D, Stein S, Weiler-Normann C, Sebode M, Mucha S, Otto B, Ellinghaus E, Stahl F, Franke A, Lohse A, Herkel J, Schramm C
J LEUKOCYTE BIOL. 2017;101(2):589-597.

"Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis: New Insights into Molecular Pathogenesis
Sebode M, Schulz L, Lohse A
INT J MOL SCI. 2017;18(9):E1954.

Anti-TNF-α for necrotizing sarcoid granulomatosis of the liver
Sebode M, Weidemann S, Wehmeyer M, Lohse A, Schramm C
HEPATOLOGY. 2017;65(4):1410-1412.

Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis
Ehlken H, Wroblewski R, Corpechot C, Arrivé L, Rieger T, Hartl J, Lezius S, Hübener P, Schulze K, Zenouzi R, Sebode M, Peiseler M, Denzer U, Quaas A, Weiler-Normann C, Lohse A, Chazouilleres O, Schramm C
PLOS ONE. 2016;11(10):e0164224.

Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis
Hartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, Hübener S, Pannicke N, Weiler-Normann C, Quaas A, Lohse A, Schramm C
J HEPATOL. 2016;65(4):769-75.

No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis
Zenouzi R, Weismüller T, Jørgensen K, Bubenheim M, Lenzen H, Hübener P, Schulze K, Weiler-Normann C, Sebode M, Ehlken H, Pannicke N, Hartl J, Peiseler M, Hübener S, Karlsen T, Boberg K, Manns M, Lohse A, Schramm C
CLIN GASTROENTEROL H. 2016;14(12):1806-1812.

Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis
Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, Zenouzi R, Glaubke C, Lohse A, Schramm C
J HEPATOL. 2015;62(3):642-6.

Phenotypic alterations of regulatory T cells in autoimmune hepatitis: causal or associated with treatment and remission?
Sebode M, Peiseler M, Weiler-Normann C, Schramm C, Lohse A, Herkel J
HEPATOLOGY. 2015;61(2):736-737.

AIH:Which Alternative for Difficult-to-Treat Patients?
Sebode M, Schramm C
DIGEST DIS. 2015;33 Suppl 2:83-7.

Natural killer T cells: Novel players in biliary disease?
Sebode M, Schramm C
HEPATOLOGY. 2015;62(4):999-1000.

Future perspective: immunomodulatory therapy for autoimmune hepatitis
Sebode M, Lohse A
DIGEST DIS. 2014;32(5):502-506.

Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms
Sebode M, Peiseler M, Franke B, Schwinge D, Schoknecht T, Wortmann F, Quaas A, Petersen B, Ellinghaus E, Baron U, Olek S, Wiegard C, Weiler-Normann C, Lohse A, Herkel J, Schramm C
J HEPATOL. 2014;60(5):1010-6.

New foe treated with old guns - supportive role of steroids in the treatment of acute severe hepatitis E
Sebode M, Pischke S, Lütgehetmann M, Polywka S, Quaas A, Lohse A, Wege H
BMC GASTROENTEROL. 2014;14(191):.

Inflammatorische Erkrankungen mit Leber- und Gelenkbeteiligung. Eine differenzialdiagnostische Herausforderung
Sebode M, Schramm C, Lohse A
INTERNIST. 2013;54(4):441-448.

Autoimmune hepatitis 2013 and beyond
Weiler-Normann C, Sebode M, Lohse A
Minerva Gastroenterol Dietol. 2013;59(2):133-41.

FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency
Peiseler M, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse A, Weiler-Normann C, Schramm C, Herkel J
J HEPATOL. 2012;57(1):125-132.

Aszites – Diagnostik, Therapie und Sekundärkomplikationen
Sebode M, Benten D
VISZERALMEDIZIN. 2012;28(2):142-148.

Autoimmunerkrankungen mit Leberbeteiligung
Sebode M, Wiegard C, Lohse A
Gastroenterologie up2date. 2012;08(02):129-141.

Letzte Aktualisierung aus dem FIS: 20.11.2024 - 23:33 Uhr